General multiple sclerosis (MS)
The areas of research currently being considered to support studies related to multiple sclerosis disease
state can be found below.
- The importance of diagnosing and treating MS early
- The importance of diligent monitoring of patients
- Validate monitoring schemes and risk mitigation regiments
- Prognostic factors of disease course e.g. markers of disease severity such as fluid biomarkers as well as imaging markers
- Managing MS-associated symptoms especially on cognitive dysfunction
- New or improved outcome measures in multiple sclerosis, incl. next generation technology and patient assessment technologies
- Multiple disease-modifying therapies incl. switching and sequencing strategies
- MS and its treatment in special populations, i.e. geriatric or pediatric patients, underrepresented minorities
- The pathogenesis of MS
Out of scope:
- Country level studies confirming established results
- Single site studies where larger data sets can be obtained from other sources (registries/MS Paths)
Although these definitions are set for Franchise they may also apply to a specific brand.
Of note: Study designs for research objectives that have been well-researched in the past need to be powered to derive statistically meaningful conclusions and provide new scientific observations.
Research support is awarded on a highly competitive basis, and submission of research proposals in these areas of interest does not guarantee that support will be awarded.
- MS - Dimethyl fumarate
- MS - Natalizumab
- MS - Daclizumab
- MS - Peginterferon beta-1a
- MS - Prolonged-release fampridine